- Home
- ECOR vs RDI Comparison
ECOR vs RDI Comparison
Compare ECOR & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- RDI
- Stock Information
- Founded
- ECOR 2005
- RDI 1937
- Country
- ECOR United States
- RDI United States
- Employees
- ECOR N/A
- RDI N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RDI Movies/Entertainment
- Sector
- ECOR Health Care
- RDI Consumer Discretionary
- Exchange
- ECOR Nasdaq
- RDI Nasdaq
- Market Cap
- ECOR 37.1M
- RDI 35.7M
- IPO Year
- ECOR 2018
- RDI N/A
- Fundamental
- Price
- ECOR $4.96
- RDI $1.54
- Analyst Decision
- ECOR Strong Buy
- RDI
- Analyst Count
- ECOR 2
- RDI 0
- Target Price
- ECOR $25.50
- RDI N/A
- AVG Volume (30 Days)
- ECOR 99.3K
- RDI 72.1K
- Earning Date
- ECOR 08-06-2025
- RDI 08-14-2025
- Dividend Yield
- ECOR N/A
- RDI N/A
- EPS Growth
- ECOR N/A
- RDI N/A
- EPS
- ECOR N/A
- RDI N/A
- Revenue
- ECOR $27,700,000.00
- RDI $219,213,000.00
- Revenue This Year
- ECOR $24.48
- RDI $5.21
- Revenue Next Year
- ECOR $44.35
- RDI $11.45
- P/E Ratio
- ECOR N/A
- RDI N/A
- Revenue Growth
- ECOR 30.16
- RDI 7.59
- 52 Week Low
- ECOR $4.16
- RDI $1.17
- 52 Week High
- ECOR $19.49
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- ECOR 41.18
- RDI 59.90
- Support Level
- ECOR $4.74
- RDI $1.48
- Resistance Level
- ECOR $5.32
- RDI $1.57
- Average True Range (ATR)
- ECOR 0.34
- RDI 0.07
- MACD
- ECOR 0.00
- RDI 0.00
- Stochastic Oscillator
- ECOR 22.22
- RDI 69.70
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.